Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HCC × Radiosurgery × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 42 Prostatic Neoplasms 30 Pancreatic Neoplasms 25 Brain Neoplasms 24 Lung Neoplasms 23 Neoplasm Metastasis 20 Melanoma 20 Carcinoma, Hepatocellular 17 Breast Neoplasms 15 Carcinoma, Renal Cell 12 Colorectal Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 8 Neoplasms 8 Small Cell Lung Carcinoma 7 Recurrence 5 Glioblastoma 5 Urinary Bladder Neoplasms 4 Sarcoma 4 Liver Neoplasms 4 Kidney Neoplasms 4 Adenocarcinoma of Lung 4 Uterine Cervical Neoplasms 3 Head and Neck Neoplasms 3 Clear-cell metastatic renal cell carcinoma 3 Cholangiocarcinoma 3 Uveal Melanoma 2 Unresectable Locally Recurrent Rectal Cancer 2 Rectal Neoplasms 2 Ovarian Neoplasms 2 Osteosarcoma 2

Interventions

nimotuzumab 1 atezolizumab 1 Radiotherapy 1 Radiosurgery 1 Immune Checkpoint Inhibitors 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡